Skip to main content

Latest SEC Filings — Page 188

Page 188 · 30 filings scored 7+ · newest 8:15 AM ET · How scores work

Thu, Aug 1330 filings
7SGRPSPAR Group, Inc.SPAR Group Returns to Profitability in Q2, Raises Full-Year Margin OutlookForm 8-K · Current report▲ Positive7NMTCNeuroOne Medical Technologies CorporationNeuroOne Q3 Revenue Up 16% to $2.0M, Gross Margin Hits 59.9%; Cash Drops to $2.0MForm 8-K · Current report● Neutral7CADLCandel Therapeutics, Inc.Candel Posts Q2 Loss, Holds $201.6M Cash, Targets Q4 BLA FilingForm 8-K · Current report● Neutral7PULMPulmatrix, Inc.Pulmatrix Reports Q2 Loss, Cash Down to $2.2M; Merger with Eos SENOLYTIX on Track for Q3 CloseForm 8-K · Current report▼ Negative7EPRXEupraxia Pharmaceuticals Inc.Eupraxia Reports Durable Symptom Relief in EoE Trial, Including First Odynophagia DataForm 6-K · Current report▲ Positive8SVVSavers Value Village, Inc.Ares Funds Upsize Secondary Offering to 20M Shares at $10.25, a 4.9% DiscountForm 424B5 · Offering▼ NegativePro8CRMDCorMedix Inc.CorMedix Q2 10-Q Reveals Material Weakness and $59M Letter of CreditForm 10-Q · Periodic report▼ NegativePro8MGTXMeiraGTx Holdings plcMeiraGTx Q2 2026: $160.7M Net Income, Bota-vec Acquisition, and FDA Breakthrough DesignationForm 8-K · Current report▲ PositivePro8DKIDarkIris Inc.DarkIris Reports 13.9% Revenue Growth but Flags Going Concern DoubtForm 6-K · Current report▼ NegativePro7DUKRDUKE Robotics Corp.Duke Robotics Q2 Loss Widens to $726K; Cash Runway Extended to 2028Form 8-K · Current report● Neutral8ELMTElmet Group Co.Elmet Group Q2 Revenue Jumps 35% to $66.4M, Backlog Hits Record $131.5MForm 8-K · Current report▲ PositivePro8XNETXunlei LtdXunlei Q2 Revenue Jumps 39% but Fair Value Loss Drives $218.5M GAAP Net LossForm 6-K · Current report▼ NegativePro7YHNAYHN Acquisition I LtdYHN Acquisition I Seeks Shareholder Approval to Extend SPAC Deadline to June 2027PRE 14A · Proxy● Neutral8BTBTBit Digital, IncBit Digital Posts $111.7M Q2 Loss on LsETH Impairment; Debt Load SurgesForm 10-Q · Periodic report▼ NegativePro8GRCEGrace Therapeutics, Inc.Grace Therapeutics Posts $15.8M Q1 Loss, Extends Cash Runway to 2028Form 8-K · Current report● NeutralPro8MGSDMaitong Sunshine Cultural Development Co., LtdMaitong Sunshine Reports Zero Revenue and $364K Loss; Flags Material WeaknessesForm 10-Q · Periodic report▼ NegativePro8AFJKAimei Health Technology Co., Ltd.Aimei Health Q2 Loss Widens, Cash Dwindles to $1,466 as SPAC Deadline LoomsForm 10-Q · Periodic report▼ NegativePro9AACBArtius II Acquisition Inc.Artius II Acquisition Moves to Liquidate as Public Shares Face RedemptionForm 8-K · Current report▼ NegativePro8VEEAVEEA INC.Veea Launches $4.35M ATM Offering Amid Distress and 1-for-20 Reverse SplitForm 424B5 · Offering▼ NegativePro7REKRRekor Systems, Inc.Rekor Q2 Loss Narrows 79% to $1.2M; Reaffirms H2 Profitability PathForm 8-K · Current report▲ Positive7RADXRadiopharm Theranostics LtdRadiopharm Seeks Shareholder Approval for Expanded A$18.5M Capital Raise and Director SPP ParticipationForm 6-K · Current report▼ Negative9ARXAccelerant HoldingsAccelerant to Be Acquired by Thoma Bravo for $20.25/Share; Q2 Earnings Beat, Guidance PulledDEFA14A · Proxy▲ PositivePro9PHIPLDT Inc.PLDT Flags Material Weakness as Auditor Pulls 2025 OpinionsForm 6-K · Current report▼ NegativePro9ARXAccelerant HoldingsThoma Bravo to Acquire Accelerant for $20.25/Share in Cash, a 49% PremiumForm 8-K · Current report▲ PositivePro7BJDXBluejay Diagnostics, Inc.Bluejay Diagnostics Completes SYMON-II Enrollment, Reports $9.6M CashForm 8-K · Current report▲ Positive8ASNDAscendis Pharma A/SAscendis Pharma Q2 2026: Revenue Soars 115%, Net Profit €207M on PRV Sale and Deferred Tax RecognitionForm 6-K · Current report▲ PositivePro7SILCSILICOM LTD.Silicom Officer Liron Eizenman Files to Sell $830K in SharesForm 144 · Insider trade▼ Negative8IRENIREN LtdIREN Delivers Horizon 1 to Microsoft, Achieves NVIDIA Exemplar Cloud StatusForm 8-K · Current report▲ PositivePro8PYXSPyxis Oncology, Inc.Pyxis Oncology Q2 2026: Cash Runway to Q2 2027, Going Concern RemainsForm 10-Q · Periodic report▼ NegativePro7PYXSPyxis Oncology, Inc.Pyxis Oncology Reports Q2 2026 Results, Extends Cash Runway into Q2 2027Form 8-K · Current report● Neutral
How Wiseek picks and scores these

How Wiseek curates this list

Every filing on this page is sourced directly from SEC EDGAR, the U.S. Securities and Exchange Commission's public filings system. Wiseek processes 8-K, 10-K, 10-Q, Form 4, Form 144, DEF 14A, Schedule 13D/A and related disclosures filed by U.S.-listed companies. The original filing is always linked from each article so readers can verify the source document directly.

How filings get scored

Each filing runs through Wiseek's importance scorer, which weights filing type, deal magnitude, insider participation, material-event flags (going-concern, restatements, executive transitions, M&A) and historical market-reaction patterns. Filings scoring below 7 on the 1–10 scale are filtered out at the database query so this list stays focused on market-moving disclosures. See our methodology for the full rubric.

Editorial standards

Wiseek does not edit the underlying SEC filing. Plain-English summaries and key-event extractions are generated from the verified source text and clearly attributed as AI-generated. Wiseek does not provide investment advice — see our editorial policy for full standards on accuracy, source disclosure, and corrections.

Track by company

Follow all SEC filings for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.